Cardlytics (NASDAQ:CDLX) Stock Rating Upgraded by Northland Capmk

Northland Capmk upgraded shares of Cardlytics (NASDAQ:CDLXFree Report) to a strong-buy rating in a research note released on Tuesday morning, Zacks.com reports.

CDLX has been the topic of a number of other reports. Needham & Company LLC restated a buy rating and issued a $12.00 target price on shares of Cardlytics in a report on Tuesday, June 11th. Northland Securities started coverage on shares of Cardlytics in a research report on Tuesday. They issued an outperform rating and a $14.00 price objective for the company. Craig Hallum lowered their price objective on shares of Cardlytics from $18.00 to $12.00 and set a buy rating for the company in a research report on Thursday, May 9th. Finally, Lake Street Capital boosted their price objective on shares of Cardlytics from $13.00 to $18.00 and gave the company a buy rating in a research report on Friday, March 15th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $12.67.

View Our Latest Research Report on Cardlytics

Cardlytics Stock Down 1.2 %

CDLX opened at $8.11 on Tuesday. The company has a current ratio of 2.13, a quick ratio of 2.13 and a debt-to-equity ratio of 1.30. Cardlytics has a 1-year low of $5.53 and a 1-year high of $20.52. The firm’s 50 day simple moving average is $10.52 and its two-hundred day simple moving average is $9.56. The company has a market capitalization of $395.61 million, a PE ratio of -1.83 and a beta of 1.67.

Cardlytics (NASDAQ:CDLXGet Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.35) earnings per share for the quarter. The firm had revenue of $67.61 million for the quarter. Cardlytics had a negative net margin of 55.23% and a negative return on equity of 25.36%.

Insider Activity at Cardlytics

In related news, CEO Karim Saad Temsamani sold 43,129 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.65, for a total transaction of $373,065.85. Following the completion of the sale, the chief executive officer now owns 385,530 shares of the company’s stock, valued at $3,334,834.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Cardlytics news, CEO Karim Saad Temsamani sold 43,129 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.65, for a total transaction of $373,065.85. Following the transaction, the chief executive officer now owns 385,530 shares in the company, valued at approximately $3,334,834.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Nicholas Hollmeyer Lynton sold 12,460 shares of the company’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $13.69, for a total transaction of $170,577.40. Following the transaction, the insider now owns 71,355 shares in the company, valued at approximately $976,849.95. The disclosure for this sale can be found here. Insiders sold 79,435 shares of company stock valued at $828,269 over the last 90 days. Insiders own 4.40% of the company’s stock.

Institutional Trading of Cardlytics

A number of hedge funds and other institutional investors have recently made changes to their positions in CDLX. Vanguard Group Inc. boosted its holdings in Cardlytics by 13.0% during the third quarter. Vanguard Group Inc. now owns 2,011,705 shares of the company’s stock worth $33,193,000 after buying an additional 231,303 shares in the last quarter. General Equity Holdings LP lifted its stake in shares of Cardlytics by 31.0% in the fourth quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock worth $5,748,000 after buying an additional 147,843 shares in the last quarter. Clear Street Markets LLC purchased a new position in shares of Cardlytics in the fourth quarter worth about $199,000. Invesco Ltd. increased its position in Cardlytics by 538.1% during the third quarter. Invesco Ltd. now owns 803,241 shares of the company’s stock worth $13,253,000 after purchasing an additional 677,354 shares during the last quarter. Finally, LPL Financial LLC increased its position in Cardlytics by 27.5% during the third quarter. LPL Financial LLC now owns 424,150 shares of the company’s stock worth $6,998,000 after purchasing an additional 91,400 shares during the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

Cardlytics Company Profile

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

See Also

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.